112733-06-9

112733-06-9 structure

Name: Zenarestat
Chemical Name: [3-(4-Bromo-2-fluorobenzyl)-7-chloro-2,4-dioxo-3,4-dihydro-1(2H)- quinazolinyl]acetic acid
CAS Number: 112733-06-9
Molecular Formula: C₁₇H₁₁BrClFN₂O₄
Molecular Weight: 441.63600
Catalog: Signaling Pathways Metabolic Enzyme/Protease Aldose Reductase
Create Date: 2018-06-09 21:09:06
Modify Date: 2024-01-06 11:09:08
Zenarestat is a potent and orally active aldose reductase inhibitor. Zenarestat improves diabetic peripheral neuropathy in Zucker diabetic fatty rats[1].

Name	[3-(4-Bromo-2-fluorobenzyl)-7-chloro-2,4-dioxo-3,4-dihydro-1(2H)- quinazolinyl]acetic acid

Description	Zenarestat is a potent and orally active aldose reductase inhibitor. Zenarestat improves diabetic peripheral neuropathy in Zucker diabetic fatty rats[1].
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> Aldose Reductase Research Areas >> Metabolic Disease Research Areas >> Neurological Disease
In Vivo	Zenarestat (3.2, 32 mg/kg; p.o.; daily for 8 weeks) inhibits nerve sorbitol accumulation in a dose-dependent manner[1]. Animal Model: Zucker diabetic fatty (ZFD) rats (type 2 diabetes models)[1] Dosage: 3.2, 32 mg/kg Administration: P.o.; daily for 8 weeks Result: At 3.2 mg/kg, zenarestat had no significant effect on the delay in F-wave minimal latency (FML) and the slowing of motor nerve conduction velocity (MNCV), although the sorbitol accumulation in the sciatic nerve was partially inhibited in ZDF rats. At 32 mg/kg zenarestat treatment improved these nerve dysfunctions in ZDF rats, along with a reduction of nerve sorbitol accumulation almost to the level of lean rats.
References	[1]. Shimoshige Y, et al. The effects of zenarestat, an aldose reductase inhibitor, on peripheral neuropathy in Zucker diabetic fatty rats. Metabolism. 2000;49(11):1395-1399.